On-chip micro-flow polystyrene bead-based immunoassay for quantitative detection of tacrolimus (FK506)

被引:64
作者
Murakami, Y
Endo, T
Yamamura, S
Nagatani, N
Takamura, Y
Tamiya, E
机构
[1] Japan Adv Inst Sci & Technol, Sch Mat Sci, Dept Chem Mat Sci, Tatsunokuchi, Ishikawa 9231292, Japan
[2] Fujisawa Pharmaceut Co Ltd, Biopharmaceut & Pharmacokinet Res Labs, Yodogawa Ku, Osaka 5328514, Japan
[3] Japan Sci & Technol Agcy, Tatsunokuchi, Ishikawa 9231292, Japan
基金
日本科学技术振兴机构;
关键词
tacrolimus (FK506); microfluidics; therapeutic drug monitoring; blood concentration; competitive immunoassay;
D O I
10.1016/j.ab.2004.07.029
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Tacrolimus (FK506) is a widely used immunosuppressant for preventing allograft rejection and the treatment of atopic dermatitis. FK506 necessitates therapeutic drug monitoring because of inter- and intrapatient variability and the lack of correlation between the administered close and the blood concentration. Previous immunoassay-based methods required a relatively long assay time and troublesome liquid-handling procedures. In the present study, we aimed to establish a rapid monitoring method for FK506 determination by using a poly(dimethylsiloxane) (PDMS)-based microfluidic device. Polystyrene beads were coated with mouse anti-FK506 antibody and placed in the flow channel. As a competitive assay, sample Solution was allowed to react in the flow channel. After the addition of the fluorogenic substrate, the fluorescent signal was observed under a microscope. As a result, the developed assay allowed a short detection time of approximately 15 min per each sample and a high sensitivity even by using only a single bead. The feasibility of performing a competitive assay using a PDMS-based antibody chip gives promising results over the existing immunoassay-based methods. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:111 / 116
页数:6
相关论文
共 19 条
[11]   A simplified whole blood enzyme-linked immunosorbent assay (ProTrac II) for tacrolimus (FK506) using proteolytic extraction in place of organic solvents [J].
MacFarlane, G ;
Scheller, D ;
Ersfeld, D ;
Jensen, T ;
Jevans, A ;
Wong, PY ;
Kobayashi, M .
THERAPEUTIC DRUG MONITORING, 1996, 18 (06) :698-705
[12]  
MURAKAMI Y, 2004, IN PRESS J NUCL MED
[13]   TACROLIMUS - A REVIEW OF ITS PHARMACOLOGY, AND THERAPEUTIC POTENTIAL IN HEPATIC AND RENAL-TRANSPLANTATION [J].
PETERS, DH ;
FITTON, A ;
PLOSKER, GL ;
FAULDS, D .
DRUGS, 1993, 46 (04) :746-794
[14]   Comparison of an ELISA and an LC/MS/MS method for measuring tacrolimus concentrations and making dosage decisions in transplant recipients [J].
Staatz, CE ;
Taylor, PJ ;
Tett, SE .
THERAPEUTIC DRUG MONITORING, 2002, 24 (05) :607-615
[15]  
STARZL TE, 1989, LANCET, V2, P1000
[16]   Evaluation of the Dade Behring Syva® EMIT 2000 tacrolimus assay on the Bayer Advia 1650 [J].
Stephen, DWS ;
Rooke, P ;
Clark, S ;
Coutts, M ;
Crowe, L ;
Docherty, D .
ANNALS OF CLINICAL BIOCHEMISTRY, 2003, 40 :697-700
[17]  
TAMURA K, 1987, TRANSPLANT P, V19, P23
[18]  
Undre NA, 1999, TRANSPL P, V31, p21S
[19]  
van Hooff JP, 1999, TRANSPL P, V31, p54S